Peptides and the TGA: An Overview
How the Australian Therapeutic Goods Administration regulates peptides, and what the regulatory pathways are.
Last updated: 4 April 2026
The TGA's regulatory role
The Therapeutic Goods Administration administers the Therapeutic Goods Act 1989. Its role is to ensure therapeutic goods supplied in Australia meet standards for safety, quality, and efficacy.
Peptide-based medicines that are approved are entered on the Australian Register of Therapeutic Goods (ARTG). Unapproved peptides generally cannot be lawfully supplied for human therapeutic use.
Regulatory pathways for peptides
Standard Registration: for established medicines with full data packages (usually takes years and significant cost). Special Access Scheme: allows qualified doctors to access unapproved peptides for patients with serious conditions who cannot be treated by approved options.
Authorised Prescriber Pathway: allows specific doctors to prescribe certain unapproved peptides under defined conditions. Clinical trials: for investigational peptides in a structured trial.
Research peptides under TGA law
Compounds labelled for research use only are not approved as therapeutic goods. Supplying them for human consumption is generally not lawful. The 'research use only' label indicates non-therapeutic status.
Importing research peptides for personal research use exists in a grey area — importing for therapeutic human use is generally prohibited.
Educational context
This page provides general educational information about TGA regulation. It is not legal advice. For specific legal questions, consult a qualified legal advisor familiar with Australian therapeutic goods law.